Skip to Content

Clinical Trials

Single Institution Feasibility Trials (R21 and R01)

The Clinical Cancer Therapy and Prevention Research (R01) initiative is seeking research project (R01) applications to conduct translational, clinical, therapeutic, and preventive studies and trials of neoplastic diseases in humans and encourages clinical researchers to collaborate with basic scientists to translate insights in cancer genetics, cancer epigenetics, and cancer biology, coupled with the development of new anti-cancer agents, into innovative cancer intervention studies and trials. The overall aims of this funding opportunity announcement (FOA) are two-fold: (1) to stimulate the development of innovative cancer prevention and therapy clinical trials with or without laboratory correlative studies; and (2) to support innovative correlative laboratory studies retrospectively and prospectively linked to therapeutic/preventive clinical trials. Investigators may address either aim in their applications.

For more information, see PA-07-356 Clinical Cancer Therapy and Prevention Research (R01)

Quick-Trials for Imaging and Image-Guided Interventions: Exploratory Grants (R21) (NCI) initiative to support clinical trials conducting preliminary evaluation of the safety and efficacy of imaging agents, as well as an assessment of imaging systems, image processing, image-guided therapy, contrast kinetic modeling, and 3-D reconstruction and other quantitative tools. The rapid translation of promising discoveries in the fields of imaging probes, methodologies, technologies and image-guided therapies to clinical practice requires timely support. This FOA will provide investigators with support for either pilot (Phase I and II) cancer clinical trials, or patient monitoring and laboratory studies.

For more information, see PAR-08-147: Quick-Trials for Imaging and Image-Guided Interventions: Exploratory Grants (R21)